{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:56:10Z","timestamp":1793876170499,"version":"4.7.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,12,1]]},"DOI":"10.1001\/jamaoncol.2021.4544","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T16:44:27Z","timestamp":1634834667000},"page":"1815","source":"Crossref","is-referenced-by-count":65,"title":["Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma"],"prefix":"10.1001","volume":"7","author":[{"given":"Laure","family":"Hirsch","sequence":"first","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Martinez Chanza","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Medical Oncology Department, Jules Bordet Institute, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrina","family":"Farah","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Braun","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nityam","family":"Rathi","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Thouvenin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie Strasbourg Europe, H\u00f4pitaux Universitaires de Strasbourg, Universit\u00e9 de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Collier","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Seront","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Department of Medical Oncology, St Luc University Hospital, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"de Velasco","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Dzimitrowicz","sequence":"additional","affiliation":[{"name":"Duke Cancer Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Universitaire Ziekenhuizen, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Alex","family":"Bowman","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine T.","family":"Lam","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Abuqayas","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Varkaris","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Duke Cancer Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Mortazavi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut de Canc\u00e9rologie Strasbourg Europe, H\u00f4pitaux Universitaires de Strasbourg, Universit\u00e9 de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Krajewski","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albig\u00e8s","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi210067r1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"coi210067r2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/bjc.2013.755","article-title":"Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine\/chemoreceptor expression.","volume":"110","author":"Wyler","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"coi210067r3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.euf.2017.12.007","article-title":"The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort.","volume":"5","author":"Sun","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"6","key":"coi210067r4","doi-asserted-by":"publisher","first-page":"e1163","DOI":"10.1016\/j.clgc.2019.08.006","article-title":"Brain metastasis from renal-cell carcinoma: an institutional study.","volume":"17","author":"Suarez-Sarmiento","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"coi210067r5","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/cncr.v113:7","article-title":"Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.","volume":"113","author":"Shuch","year":"2008","journal-title":"Cancer"},{"key":"coi210067r6","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1200\/JCO.2016.34.15_suppl.4561","article-title":"Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): experience from Gustave Roussy (IGR).","volume":"34","author":"Guida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi210067r7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/neuonc\/noy099","article-title":"Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.","volume":"20","author":"Sperduto","year":"2018","journal-title":"Neuro Oncol"},{"key":"coi210067r8","article-title":"Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.","volume":"9","author":"Patil","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"coi210067r9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group.","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi210067r10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.clgc.2013.09.008","article-title":"A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.","volume":"12","author":"Chevreau","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"coi210067r11","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"coi210067r12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi210067r13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial.","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10275","key":"coi210067r14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"coi210067r15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.","volume":"20","author":"Mart\u00ednez Chanz\u00e1","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi210067r16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clgc.2019.05.002","article-title":"Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population.","volume":"17","author":"Peverelli","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"coi210067r17","article-title":"Brain complete response to cabozantinib prior to radiation therapy in metastatic renal cell carcinoma.","volume":"2019","author":"Uche","year":"2019","journal-title":"Case Rep Urol"},{"issue":"5","key":"coi210067r18","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1016\/j.clgc.2018.06.005","article-title":"Exceptional response to cabozantinib of rapidly evolving brain metastases of renal cell carcinoma: a case report and review of the literature.","volume":"16","author":"Ciccarese","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"coi210067r19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13256-018-1875-9","article-title":"Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.","volume":"12","author":"N\u00e9grier","year":"2018","journal-title":"J Med Case Rep"},{"issue":"23","key":"coi210067r20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study.","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi210067r21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-017-2398-8","article-title":"Comparing available criteria for measuring brain metastasis response to immunotherapy.","volume":"132","author":"Qian","year":"2017","journal-title":"J Neurooncol"},{"issue":"6","key":"coi210067r22","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group.","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"coi210067r23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","article-title":"Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.","volume":"135","author":"McGregor","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9","key":"coi210067r24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"coi210067r25","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2017.35.15_suppl.4569","article-title":"Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC).","volume":"35","author":"Derosa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi210067r26","first-page":"112","article-title":"XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.","volume":"13","author":"Zhang","year":"2010","journal-title":"IDrugs"},{"issue":"22","key":"coi210067r27","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer.","volume":"59","author":"Heffron","year":"2016","journal-title":"J Med Chem"},{"issue":"11","key":"coi210067r28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi210067r29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.6004\/jnccn.2020.7634","article-title":"Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma.","volume":"19","author":"Kotecha","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"coi210067r30","unstructured":"Evaluation of cabozantinib in metastatic renal cell carcinoma (mRCC) with brain metastases (CABRAMET). ClinicalTrials.gov identifier: NCT03967522. Updated February 8, 2021. Accessed September 21, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03967522?term=NCT03967522&draw=2&rank=1"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2784989\/jamaoncology_hirsch_2021_oi_210067_1639155138.07449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T16:19:26Z","timestamp":1639671566000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2784989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.4544","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}